Archive for 'Inhaler' Category:

By Matthew Allen: Friday 8th May, 2015

Drug Delivery on the Cote D’Azur

It’s a hard life being a Drug Delivery Device Developer. Four days on the Cote D’Azur with the world’s leading Inhaler experts at the Respiratory Drug Delivery (RDD) Conference has just come to an end. It was a great opportunity to catch up with old friends as well as introduce Cambridge Consultants to new delegates […]

By Matthew Allen: Friday 8th May, 2015

Drug Delivery – emerging markets

I’ve just returned from Cambridge Consultants Drug Delivery Workshop in India with invited thought leaders from across the Indian Pharma business. The discussion theme was market, innovation and technology drivers in emerging markets. The workshop provided an alternative perspective to Cambridge Consultants Drug Delivery workshop in 2012 which concentrated on predictions for India Pharma’s ambitions in […]

Diabetes Drug Delivery Devices
By Matthew Allen: Wednesday 16th July, 2014

Diabetes Drug Delivery Devices – the next chapter

As drug delivery device developers we are well used to injection pens. When they first appeared they changed the lives of diabetes patients creating a user friendly and discrete way to administer life saving insulin. We have seen innovation over the years but some recent device news may herald a new chapter for patients. Mannkinds […]

By Matthew Allen: Wednesday 7th May, 2014

Respiratory Drug Delivery 2014 – Device Development session

On day three of RDD 2014 the device developers take centre stage. It’s great to see 3M presenting their dose by dose counter for MDI. Cambridge Consultants collaborated with 3M on aspects of development, scale up and design for manufacture of the 3M Integrated Dose by Dose Counter which is now commercialised and FDA-approved in conjunction with […]

By Matthew Allen: Tuesday 6th May, 2014

What can device developers do about Drug Delivery in emerging markets?

At Respiratory Drug Delivery 2014 fascinating analysis of emerging markets. According to some estimates, COPD is predicted to become the third leading cause of death worldwide by 2030 and most of those patients will live in developing countries. Whilst in the West a metered dose inhaler might be available to 100% of its target patients within 5 years, it can […]

By Matthew Allen: Tuesday 6th May, 2014

Respiratory Drug Delivery 2014

Here at Respiratory Drug Delivery 2014 there are some interesting topics for Drug Delivery experts to discuss. Firstly I’m pleased to see some of our work with Novartis and Nektar being presented. Results from the programme, to develop a breakthrough integrated drug-device combination for the treament of gram-negative pneumonia, show how driving a mesh nebuliser at its resonant frequency and varying voltage using a proprietary […]

By Matthew Allen: Sunday 2nd March, 2014

Drug Delivery – if the price is right

When the market leaders in the US Pharmacy Benefit Management market CVS Caremark and Express Scripts recently made a number of formulary changes the biggest to lose coverage was Glaxo’s blockbuster Advair Diskus dry powder inhaler. Advair has been moved to the “Not Covered” category apparently due to its high costs judged to be disproportional to clinical benefit compared […]

Inhaler development
By Matthew Allen: Friday 13th September, 2013

Inhaler development – the next chapter

In the world of inhaler development, one subject has dominated Cambridge Consultants’ discussions with industry, the route to the holy grail of a generic Advair, GSK’s $8billion a year asthma treatment and the third largest selling drug in the world. Recent guidance from the FDA finally makes the development hurdles clear for inhaler developers  and could allow generic copies of Advair […]

innovative inhaler for drug delivery
By Andrew Barrett: Friday 26th April, 2013

What’s driving the buoyancy in drug delivery device development?

The demand for Drug delivery device development for products such as auto-injectors and inhalers has, for several years, shown it to be a particularly buoyant market.  So despite a backdrop of depressed global economics, what’s driving this growth and which sectors is it coming from? Andrew Barrett, associate director in our global Medical Technology division […]


Recent Posts

Posts by categories